Reversal of retinal ganglion cell dysfunction happens after IOP reduction

Article

A study has shown that the surgical reduction of IOP causes the reversal of retinal ganglion cell (RGC) dysfunction.

A study has shown that the surgical reduction of IOP causes the reversal of retinal ganglion cell (RGC) dysfunction. It was also found that the pattern electroretinogram optimized for glaucoma screening (PERGLA) can be a non-invasive technique to measure RGC function.

Mitra Sehi, Research Assistant Professor of Ophthalmology at Bascom Palmer Eye Institute, University of Miami, USA, conducted a prospective cohort study of 47 eyes of 47 patients with uncontrolled IOP. The patients underwent a total ocular examination, arterial blood pressure, standard automated perimetry (SAP) and PERGLA before surgery and three months after surgery.

The results indicated that mean postoperative IOP was significantly reduced compared with preoperative IOP. PERGLA amplitude after surgery increased compared to preoperative PERGLA amplitude. Thirty-four of the 47 eyes underwent trabeculectomy with antifibrosis therapy, 13 eyes had glaucoma drainage implant surgery.

The conclusion was that the reversal of RGC dysfunction happens after surgical reduction of IOP and can be measured using PERGLA.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.